Tyrosine kinase receptor transactivation associated to G protein-coupled receptors

Current Drug Targets

Volumn 11, Issue 9, 2010, Pages 1169-1180

  Almendro, Vanessa ^a   García Recio, Susana ^a   Gascón, Pedro ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

C Src; Chemoresistance; GPCR; Inflammation; Lipid rafts; MAPK; MMPs; TKR

Indexed keywords

ADAM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; TACHYKININ; TYROSINE KINASE RECEPTOR;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL TRANSFORMATION; COLON CANCER; DNA SYNTHESIS; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; LIPID RAFT; METASTASIS; MITOGENESIS; NONHUMAN; ONCOGENE SRC; PANCREAS CANCER; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR GROWTH;

ADAM PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASES; MEMBRANE MICRODOMAINS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR CROSS-TALK; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 78651279608     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010792006807     Document Type: Article

References (111)

1. Piiper A, Zeuzem S. Receptor tyrosine kinases are signaling intermediates of G protein-coupled receptors. Curr Pharm Des 2004; 10(28): 3539-45.
2. Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 2008; 13: 1857-65.
3. Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 1995; 80(2): 249-57.
4. Lowes VL, Ip NY, Wong YH. Integration of signals from receptor tyrosine kinases and g protein-coupled receptors. Neurosignals 2002; 11(1): 5-19.
5. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007; 7(2): 79-94.
6. Ma YC, Huang J, Ali S, Lowry W, Huang XY. Src tyrosine kinase is a novel direct effector of G proteins. Cell 2000; 102(5): 635-46.
7. Chen CH, Cheng TH, Lin H, et al. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2- containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol Pharmacol 2006; 69(4): 1347-55.
8. Cheng-Hsien C, Yung-Ho H, Yuh-Mou S, et al. Src homology 2- containing phosphotyrosine phosphatase regulates endothelin-1- induced epidermal growth factor receptor transactivation in rat renal tubular cell NRK-52E. Pflugers Arch 2006; 452(1): 16-24.
9. Tal TL, Graves LM, Silbajoris R, Bromberg PA, Wu W, Samet JM. Inhibition of protein tyrosine phosphatase activity mediates epidermal growth factor receptor signaling in human airway epithelial cells exposed to Zn2+. Toxicol Appl Pharmacol 2006; 214(1): 16-23.
10. Gao Y, Tang S, Zhou S, Ware JA. The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase Cdependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor. J Pharmacol Exp Ther 2001; 296(2): 426-33.
11. Dajani OF, Meisdalen K, Guren TK, et al. Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes. J Cell Physiol 2008; 214(2): 371-80.
12. Caja L, Ortiz C, Bertran E, et al. Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Cell Signal 2007; 19(4): 683-94.
13. Natarajan K, Berk BC. Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases. Methods Mol Biol 2006; 332: 51-77.
14. Pattarozzi A, Gatti M, Barbieri F, et al. 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor- 1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol Pharmacol 2008; 73(1): 191-202.
15. Cabioglu N, Summy J, Miller C, et al. CXCL-12/stromal cellderived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005; 65(15): 6493-7.
16. Razandi M, Pedram A, Park ST, Levin ER. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 2003; 278(4): 2701-12.
17. Joo CK, Kim HS, Park JY, Seomun Y, Son MJ, Kim JT. Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways. Oncogene 2008; 27(5): 614-28.
18. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res 2009; 69(2): 475-82.
19. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 2007; 9(5): R63.
20. Darmoul D, Gratio V, Devaud H, Peiretti F, Laburthe M. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Mol Cancer Res 2004; 2(9): 514-22.
21. Maupas-Schwalm F, Robinet C, Auge N, et al. Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells. Cancer Res 2005; 65(2): 526-32.
22. Grant K, Knowles J, Dawas K, Burnstock G, Taylor I, Loizidou M. Mechanisms of endothelin 1-stimulated proliferation in colorectal cancer cell lines. Br J Surg 2007; 94(1): 106-12.
23. Cheng K, Raufman JP. Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. Biochem Pharmacol 2005; 70(7): 1035-47.
24. Shida D, Kitayama J, Mori K, Watanabe T, Nagawa H. Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Res 2005; 65(20): 9159-63.
25. Shida D, Kitayama J, Yamaguchi H, et al. Sphingosine 1-phosphate transactivates c-Met as well as epidermal growth factor receptor (EGFR) in human gastric cancer cells. FEBS Lett 2004; 577(3): 333-8.
26. Shida D, Kitayama J, Yamaguchi H, et al. Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells. Biochem Biophys Res Commun 2005; 327(3): 907-14.
27. Piiper A, Elez R, You SJ, et al. Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon. J Biol Chem 2003; 278(9): 7065-72.
28. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c- Src interactions in breast cancer. Breast Cancer Res 2000; 2(3): 203-10.
29. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c- Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999; 274(12): 8335-43.
30. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001; 20(12): 1465-75.
31. Mueller KL, Hunter LA, Ethier SP, Boerner JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008; 68(9): 3314-22.
32. Lu Y, Li X, Liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 2007; 67(17): 8240-7.
33. Fu YN, Yeh CL, Cheng HH, et al. EGFR mutants found in nonsmall cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. Oncogene 2008; 27(7): 957-65.
34. Qin B, Ariyama H, Baba E, et al. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharmacol 2006; 58(5): 577-84.
35. Yue W, Fan P, Wang J, Li Y, Santen RJ. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007; 106(1-5): 102-10.
36. Fan P, Wang J, Santen RJ, Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 2007; 67(3): 1352-60.
37. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006; 97(3): 263-74.
38. Bao J, Gur G, Yarden Y. Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci U S A 2003; 100(5): 2438-43.
39. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410(6824): 50-6.
40. Black PC, Mize GJ, Karlin P, et al. Overexpression of proteaseactivated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate 2007; 67(7): 743-56.
41. Watanabe O, Shimizu T, Imamura H, et al. Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res 2003; 23(4): 3215-21.
42. Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets 2006; 7(8): 1043-52.
43. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10(1): 25-38.
44. Ohtsu H, Dempsey PJ, Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 2006; 291(1): C1-10.
45. Ohkubo S, Nakahata N. [Role of lipid rafts in trimeric G proteinmediated signal transduction]. Yakugaku Zasshi 2007; 127(1): 27-40.
46. Puri C, Tosoni D, Comai R, et al. Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains. Mol Biol Cell 2005; 16(6): 2704-18.
47. Head BP, Patel HH, Roth DM, et al. Microtubules and actin microfilaments regulate lipid raft/caveolae localization of adenylyl cyclase signaling components. J Biol Chem 2006; 281(36): 26391-9.
48. Ostrom RS, Insel PA. The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology. Br J Pharmacol 2004; 143(2): 235-45.
49. Chini B, Parenti M. G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there? J Mol Endocrinol 2004; 32(2): 325-38.
50. Navratil AM, Bliss SP, Berghorn KA, et al. Constitutive localization of the gonadotropin-releasing hormone (GnRH) receptor to low density membrane microdomains is necessary for GnRH signaling to ERK. J Biol Chem 2003; 278(34): 31593-602.
51. Monastyrskaya K, Hostettler A, Buergi S, Draeger A. The NK1 receptor localizes to the plasma membrane microdomains, and its activation is dependent on lipid raft integrity. J Biol Chem 2005; 280(8): 7135-46.
52. Hur EM, Park YS, Lee BD, et al. Sensitization of epidermal growth factor-induced signaling by bradykinin is mediated by c-Src. Implications for a role of lipid microdomains. J Biol Chem 2004; 279(7): 5852-60.
53. Jahn T, Leifheit E, Gooch S, Sindhu S, Weinberg K. Lipid rafts are required for Kit survival and proliferation signals. Blood 2007; 110(6): 1739-47.
54. Singh D, Joshi DD, Hameed M, et al. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci USA 2000; 97(1): 388-93.
55. Castagliuolo I, Valenick L, Liu J, Pothoulakis C. Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem 2000; 275(34): 26545-50.
56. Liu Y, Sun R, Wan W, et al. The involvement of lipid rafts in epidermal growth factor-induced chemotaxis of breast cancer cells. Mol Membr Biol 2007; 24(2): 91-101.
57. Bionda C, Athias A, Poncet D, et al. Differential regulation of cell death in head and neck cell carcinoma through alteration of cholesterol levels in lipid rafts microdomains. Biochem Pharmacol 2008; 75(3): 761-72.
58. Lambert S, Vind-Kezunovic D, Karvinen S, Gniadecki R. Ligandindependent activation of the EGFR by lipid raft disruption. J Invest Dermatol 2006; 126(5): 954-62.
59. Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS, Hong SJ. Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate 2007; 67(10): 1061-9.
60. Orr G, Hu D, Ozcelik S, Opresko LK, Wiley HS, Colson SD. Cholesterol dictates the freedom of EGF receptors and HER2 in the plane of the membrane. Biophys J 2005; 89(2): 1362-73.
61. Huang Y, Yang J, Shen J, Chen FF, Yu Y. Sphingolipids are involved in N-methyl-N'-nitro-N-nitrosoguanidine-induced epidermal growth factor receptor clustering. Biochem Biophys Res Commun 2005; 330(2): 430-8.
62. Feng YH, Ding Y, Ren S, Zhou L, Xu C, Karnik SS. Unconventional homologous internalization of the angiotensin II type-1 receptor induced by G-protein-independent signals. Hypertension 2005; 46(2): 419-25.
63. Balbis A, Parmar A, Wang Y, Baquiran G, Posner BI. Compartmentalization of signaling-competent epidermal growth factor receptors in endosomes. Endocrinology 2007; 148(6): 2944-54.
64. Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene 2008; 27(32): 4434-45.
65. Xiao D, Qu X, Weber HC. Activation of extracellular signalregulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell Signal 2003; 15(10): 945-53.
66. Gschwind A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 2002; 62(21): 6329-36.
67. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72(11): 1605-21.
68. Donnini S, Finetti F, Solito R, et al. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J 2007; 21(10): 2418-30.
69. Xu L, Han C, Wu T. A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth. J Biol Chem 2006; 281(45): 33982-96.
70. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8(3): 289-93.
71. Sales KJ, Maudsley S, Jabbour HN. Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3',5'-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways. Mol Endocrinol 2004; 18(6): 1533-45.
72. Howe LR, Chang SH, Tolle KC, et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005; 65(21): 10113-9.
73. Xu K, Shu HK. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 2007; 67(13): 6121-9.
74. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 2006; 103(5): 1492-7.
75. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gsaxin- beta-catenin signaling axis. Science 2005; 310(5753): 1504-10.
76. Li X, Wei J, Tai HH. Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells. Arch Biochem Biophys 2007; 467(1): 20-30.
77. Zhao D, Zhan Y, Koon HW, et al. Metalloproteinase-dependent transforming growth factor-alpha release mediates neurotensinstimulated MAP kinase activation in human colonic epithelial cells. J Biol Chem 2004; 279(42): 43547-54.
78. Keates S, Keates AC, Katchar K, Peek RM, Jr., Kelly CP. Helicobacter pylori induces up-regulation of the epidermal growth factor receptor in AGS gastric epithelial cells. J Infect Dis 2007; 196(1): 95-103.
79. Joh T, Kataoka H, Tanida S, et al. Helicobacter pylori-stimulated interleukin-8 (IL-8) promotes cell proliferation through transactivation of epidermal growth factor receptor (EGFR) by disintegrin and metalloproteinase (ADAM) activation. Dig Dis Sci 2005; 50(11): 2081-9.
80. Haddow A. Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing? Adv Cancer Res 1972; 16: 181-234.
81. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315(26): 1650-9.
82. Xu KP, Yin J, Yu FS. SRC-family tyrosine kinases in wound- and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2006; 47(7): 2832-9.
83. Yahata Y, Shirakata Y, Tokumaru S, et al. A novel function of angiotensin II in skin wound healing. Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated EGF receptor transactivation. J Biol Chem 2006; 281(19): 13209-16.
84. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 2001; 21(19): 6387-94.
85. Meng D, Shi X, Jiang BH, Fang J. Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species. Free Radic Biol Med 2007; 42(11): 1651-60.
86. Hirota K, Murata M, Itoh T, Yodoi J, Fukuda K. Redox-sensitive transactivation of epidermal growth factor receptor by tumor necrosis factor confers the NF-kappa B activation. J Biol Chem 2001; 276(28): 25953-8.
87. Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ Res 2005; 96(2): 172-9.
88. He H, Levitzki A, Zhu HJ, Walker F, Burgess A, Maruta H. Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. J Biol Chem 2001; 276(29): 26741-4.
89. Azar ZM, Mehdi MZ, Srivastava AK. Insulin-like growth factor type-1 receptor transactivation in vasoactive peptide and oxidantinduced signaling pathways in vascular smooth muscle cells. Can J Physiol Pharmacol 2007; 85(1): 105-11.
90. Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 2000; 275(29): 22583-9.
91. Zhou Q, Meng D, Yan B, Jiang BH, Fang J. Transactivation of epidermal growth factor receptor by insulin-like growth factor 1 requires basal hydrogen peroxide. FEBS Lett 2006; 580(22): 5161-6.
92. Wang D, Patil S, Li W, Humphrey LE, Brattain MG, Howell GM. Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 2002; 21(18): 2785-96.
93. Huether A, Hopfner M, Sutter AP, Baradari V, Schuppan D, Scherubl H. Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 2006; 12(32): 5160-7.
94. Kuribayashi A, Kataoka K, Kurabayashi T, Miura M. Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells. Endocrinology 2004; 145(11): 4976-84.
95. Hurbin A, Dubrez L, Coll JL, Favrot MC. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. Ann N Y Acad Sci 2003; 1010: 354-7.
96. Burgaud JL, Baserga R. Intracellular transactivation of the insulinlike growth factor I receptor by an epidermal growth factor receptor. Exp Cell Res 1996; 223(2): 412-9.
97. Rosano L, Di Castro V, Spinella F, et al. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res 2007; 67(13): 6351-9.
98. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278(37): 35451-7.
99. Banu N, Buda A, Chell S, et al. Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. Cell Prolif 2007; 40(5): 768-79.
100. Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 2006; 207(1): 261-70.
101. Mann M, Sheng H, Shao J, et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120(7): 1713-9.
102. Mori K, Kitayama J, Shida D, Yamashita H, Watanabe T, Nagawa H. Lysophosphatidic acid-induced effects in human colon carcinoma DLD1 cells are partially dependent on transactivation of epidermal growth factor receptor. J Surg Res 2006; 132(1): 56-61.
103. Miyamoto S, Hirata M, Yamazaki A, et al. Heparin-binding EGFlike growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004; 64(16): 5720-7.
104. Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat 2008; 111(2): 241-50.
105. Sotomayor S, Carmena MJ, Schally AV, et al. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormonereleasing hormone. Int J Oncol 2007; 31(5): 1223-30.
106. Stewart JR, O'Brian CA. Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells. Mol Cancer Ther 2005; 4(5): 726-32.
107. Gregory CW, Whang YE, McCall W, et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005; 11(5): 1704-12.
108. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999; 96(10): 5458-63.
109. Chan DC, Gera L, Stewart JM, et al. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res 2002; 8(5): 1280-7.
110. Thomas SM, Bhola NE, Zhang Q, et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006; 66(24): 11831-9.
111. Zhang Q, Bhola NE, Lui VW, et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 2007; 6(4): 1414-24.